Prostate Cancer Clinical Trial
Official title:
Exercise Intervention to Reduce Adverse Quality of Life Effects From Androgen Deprivation Therapy for Prostate Cancer - Randomized Clinical Trial
This study evaluates effects of supervised exercise in reducing adverse effects of hormonal treatment, increasing quality of life and in inducing a long-term change into more active lifestyle in prostate cancer patients on androgen deprivation therapy. All participants will attend a starting lecture at the beginning of the trial, after which they are randomly allocated to attend 3 months of either supervised or non-supervised exercise program. Leisure time activity, quality of life, blood sugar and cholesterol values, and body composition of participants will be evaluated at three time-points; at recruitment, after 12 weeks and after 24 weeks. Effects on quality of life will also be qualitatively evaluated with single- and group interviews.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | August 15, 2021 |
Est. primary completion date | August 15, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Undergoing castration treatment for prostate cancer - Informed consent for the study Exclusion Criteria: - Unable to participate in exercise (ECOG 2 or greater) - High bone fracture risk (as judged by the primary physician) - Unable to understand spoken and written instructions in Finnish |
Country | Name | City | State |
---|---|---|---|
Finland | Tampere University Hospital | Tampere |
Lead Sponsor | Collaborator |
---|---|
Tampere University Hospital | Varalan urheiluopisto |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Time to castration resistance | Time to castration resistance as defined by two consecutive rising PSA levels and increase of 50% or more from the nadir. Measured as months between the study recruitment and first record of castration resistance. Information obtained from patient files. | Followed yearly for up to 15 years from randomization | |
Other | Time to death | Time to death due to any cause. Measured as months between the study recruitment and date of death. Information obtained from patient files and national death certificate registry. | Followed yearly for up to 15 years from randomization | |
Other | Time to prostate cancer death | Time to death due to prostate cancer. Measured as months between the study recruitment and date of death. Information obtained from patient files and national death certificate registry. | Followed yearly for up to 15 years from randomization | |
Other | Bone fractures | Occurrence of any bone fracture requiring either conservative or operative management. Information obtained from patient files and national hospital discharge registry. Fracture site and it's management are recorded. | Followed yearly for up to 15 years from randomization | |
Primary | Daily total activity | Daily activity as measured by wrist activity monitor worn by the participants at all times during the study. Measured as metabolic equivalents of task (MET) units. Range from 0.9 to 23. | At randomization and twice more at 12 week intervals | |
Primary | Fasting plasma total cholesterol | Value measure in mmol/l | At randomization and twice more at 12 week intervals | |
Primary | Fasting plasma LDL cholesterol | Value measure in mmol/l | At randomization and twice more at 12 week intervals | |
Primary | Fasting plasma HDL cholesterol | Value measure in mmol/l | At randomization and twice more at 12 week intervals | |
Primary | Fasting plasma triglycerides | Value measure in mmol/l | At randomization and twice more at 12 week intervals | |
Primary | Fasting plasma glucose level | Value measured in mmol/l | At randomization and twice more at 12 week intervals | |
Primary | Blood glycated hemoglobin (HbA1C) level | Value measured in mmol/mol | At randomization and twice more at 12 week intervals | |
Primary | Overall quality of life | Score from validated survey EORTC QLQ-C30, score range from 0-100, with 100 denoting the highest quality of life | At randomization and twice more at 12 week intervals | |
Primary | Prostate cancer-specific quality of life | Score from validated survey EORTC QLQ-PR25, score range from 0-100, with 100 denoting the highest quality of life | At randomization and twice more at 12 week intervals | |
Secondary | Change in daily activity after the intervention | Change in daily activity of the supervised exercise group after completion of 12 weeks of supervised exercise as measured by wrist activity monitor in MET units, range from 0.9 to 23. | Measured daily for 12 weeks' time after the intervention | |
Secondary | Subjective adverse effects of castration treatment | The effect of supervised exercise on subjective adverse effects of castration treatment for prostate cancer. Qualitative assessment in three individual interviews and one group interview. No scaling used as this is a qualitative rather than quantitative end-point | At randomization and twice more at 12 week intervals | |
Secondary | Lean body mass | Bioimpedance-based measurement of lean body mass as percentage of total body mass measured with TANITA MC-780 device | At randomization and twice more at 12 week intervals | |
Secondary | Muscle mass | Bioimpedance-based measurement of muscle mass as percentage of total body mass measured with TANITA MC-780 device | At randomization and twice more at 12 week intervals | |
Secondary | Skeletal mass | Bioimpedance-based measurement of skeletal mass as percentage of total body mass measured with TANITA MC-780 device measured with TANITA MC-780 device | At randomization and twice more at 12 week intervals | |
Secondary | Fat mass | Bioimpedance-based measurement of fat mass as percentage of total body mass measured with TANITA MC-780 device measured with TANITA MC-780 device | At randomization and twice more at 12 week intervals | |
Secondary | Metabolic age | Metabolic age measured with bioimpedance-based TANITA MC-780 device | At randomization and twice more at 12 week intervals | |
Secondary | Systolic blood pressure | Value measured in mmHg | At randomization and twice more at 12 week intervals | |
Secondary | Diastolic blood pressure | Value measured in mmHg | At randomization and twice more at 12 week intervals |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |